

Subject name, address	Effective date	Subject name, address	Effective date	Subject name, address	Effective date
CHICAGO, IL PISANO, SALLIE	3/20/2005	FRUITA, CO VALENCIA, MARIA	3/20/2005	LOS ANGELES, CA CHIANG, PHILIP	3/20/2005
LACEY, WA POOLE, WILLIAM	3/20/2005	DENVER, CO VALENTINE, CHRISTINE	3/20/2005	MOUNTAIN VIEW, CA FERNANDO, ANTONIO	3/20/2005
EAGLESVILLE, TN POULSEN, JERRY W	3/20/2005	RICHMOND, VA VANDENBOS, GREGORY	3/20/2005	PHILADELPHIA, PA LINDLY, MAURICE	3/20/2005
VALLEY CITY, UT POYATOS, DANILO	3/20/2005	RENO, NV VAWTER, KAREN	3/20/2005	SALINAS, CA MULLINAX, JEFFREY	3/20/2005
VICTORVILLE, CA PRONTO, DAVID	3/20/2005	COEUR D'ALENE, ID WALLACE, PATRICK	3/20/2005	WINDSOR, CA NEWBY, EDGAR	3/20/2005
HUDSON FALLS, NY PRUGH, JAMES	3/20/2005	ABINGDON, VA WIJNHAMER, JAN	3/20/2005	LAWTON, OK PASCALE, MICHELE	3/20/2005
SCOTTSDALE, AZ RAIMAN, GARII	3/20/2005	BELLINGHAM, WA WILLIAMS, MICHELLE	3/20/2005	AUGUSTA, GA RAPPA, RICHARD	3/20/2005
CONCORD, CA ROSS, LINDA	3/20/2005	PAINTSVILLE, KY WILSON, DONNA	3/20/2005	N HAVEN, CT	
EL DORADO, KS SABATINO, DAVID	3/20/2005	JASPER, TX WRIGHT, STEVIE	3/20/2005	CMP	
ELIZABETHTON, TN SARVIS, AMANDA	3/20/2005	SEYMOUR, TN YOUNG, SANDRA	3/20/2005	O'CONNOR, THOMAS	2/28/2005
FREMONT, NC SAVAGE, SANDRA	3/20/2005	CARTERVILLE, IL ZEGARRA, GLORIA	3/20/2005	MILWAUKEE, WI	
S BOSTON, MA SAYED, SAQUIB	3/20/2005	GLENDALE, CA		Dated: March 2, 2005.	
CRANFORD, NJ SCHAEFFER, BRANDON	3/20/2005	FRAUD/KICKBACKS/PROHIBITED ACTS/ SETTLEMENT AGREEMENTS			
CHICAGO, IL SCHWARZ, ANN	3/20/2005	MED-CON, INC	12/29/2004	Katherine B. Petrowski, Director, Exclusions Staff, Office of Inspector General.	
RANDOLPH, MA SCOTT, OTIS	3/20/2005	PAINTSVILLE, KY PRICE, HARRY	9/20/2004	[FR Doc. 05-4680 Filed 3-9-05; 8:45 am]	
ABINGTON, PA SEJALBO, MARYANN	3/20/2005	MARTINSBURG, VA SHAW, JOHN	12/29/2004	BILLING CODE 4150-04-P	
HAYWARD, CA SHELL, JOAN-MARIE	3/20/2005	PAINTSVILLE, KY		DEPARTMENT OF HEALTH AND HUMAN SERVICES	
PORT HADLOCK, WA SHERMAN, AHRON	3/20/2005	OWNED/CONTROLLED BY CONVICTED ENTITIES			
EUREKA, CA SHINDORE, SHREELAL	3/20/2005	AMERICAN FAMILY PHARMA- CEUTICALS, INC	3/20/2005	National Institutes of Health	
NAPLES, FL SHORT, LEA ANN	3/20/2005	NAPLES, FL CONVENIENT MEDICAL SERVICES, INC	3/20/2005	Proposed Collection; Comment Request; Assessment of the Use of Special Funding on Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes	
NEW ALBANY, IN SILVA, LINDA	3/20/2005	NAPLES, FL LADD MANAGEMENT COR- PORATION	3/20/2005	SUMMARY: In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.	
IONE, CA SIMPSON, LISA	3/20/2005	LEAWOOD, KS MARIN CHIROPRACTIC, INC VAN NUYS, CA	3/20/2005	Proposed Collection: <i>Title:</i> Assessment of the Use of Special Funding for Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997 (Pub. L. 105-33), the FY 2001 Consolidated Appropriations Act (Pub. L. 106-554), and the Public Health Service Act Amendment for Diabetes (Pub. L. 107-360). <i>Type of Information Collection Request:</i> Revision, OMB control number 0925- 0503; expiration date: 06/30/2005. <i>Need and Use of Information Collection:</i> This	
LOUISVILLE, KY SMITH, LESLIE	3/20/2005	MICHAEL E SMITH, D P M, P A	3/20/2005		
TEMPE, AZ SMITH, SUSAN	3/20/2005	ORLANDO, FL MOBILE DENTISTRY, LLC	3/20/2005		
ROCKFORD, IL SMITH, TRICIA	3/20/2005	NEW CASTLE, PA PAIN RELIEF MEDICAL CEN- TER	3/20/2005		
OSSIPEE, NH SOUSA, BONNIE	3/20/2005	VAN NUYS, CA S FT MYERS MEDICAL CEN- TER, INC	3/20/2005		
STOCKTON, CA STAPLETON, KELLY	3/20/2005	FT MYERS, FL SHREELAL M SHINDORE, MD, PA	3/20/2005		
CRESTWOOD, IL STELLHORN, JEANNE	3/20/2005	NAPLES, FL SYNERGISTICS MEDICAL CARE PA	3/20/2005		
CAHOKIA, IL STEVENS, ANNA	3/20/2005	LEAWOOD, KS			
ROOSEVELT, UT STOLLOF, KELLY	3/20/2005	DEFAULT ON HEAL LOAN			
INDIO, CA STROMBERG, WILLIAM	3/20/2005	BAKER, WALTER	3/20/2005		
DE SOTO, IL SUPPLEE, PENNY	3/20/2005	VALLEJO, CA BARNETT, RUTH	2/1/2005		
WEST CHESTER, PA SUSS, BEVERLY	3/20/2005	DETROIT, MI BELL, HERMAN	3/20/2005		
GRAFTON, MA SUTTON, CURTIS	3/20/2005				
LAYTON, UT TAYLOR, REGINA	3/20/2005				
CHICAGO, IL TEE, MIKE	3/20/2005				
AURORA, CO VAHLE, TREVOR	3/20/2005				

survey will be one source of input into a statutorily mandated assessment and report to the Congress on special funding for research on type 1 diabetes provided by the Balanced Budget Act of 1997, (Pub. L. 105-33), the FY 2001 Consolidated Appropriations Act, (Pub. L. 106-554), and the Public Health Service Act Amendment for Diabetes, (Pub. L. 107-360). Collectively, these Acts provided \$1.14 billion in special funds to the Department of Health and Human Services (HHS) for research aimed at understanding, treating and preventing type 1 diabetes and its complications. The Secretary of HHS subsequently designated to NIDDK the lead responsibility in the Department for developing a process for allocation of these funds. The primary objective of the survey is to gain information, via a brief questionnaire, from NIH research grantees, who were the primary recipients of these special funds, concerning their views on the impact of the type 1 diabetes research funding with respect to: (1) Advancing scientific accomplishments involving innovative, clinically relevant, and multidisciplinary research on type 1 diabetes; (2) developing resources or reagents useful for type 1 diabetes research; and (3) increasing the number and quality of type 1 diabetes investigators. The responses will provide valuable information concerning how the funds have facilitated research as intended by these Acts of Congress. The results will also help determine how research progress from these special congressional initiatives fits within the continuum of diabetes research, and how these funds have contributed to the field of type 1 diabetes research and NIH efforts to combat this challenging health problem. Information from this study will aid in evaluation of the process by which the research goals for use of the special type 1 diabetes funds have been developed and are being pursued. Responses already collected from this survey were analyzed as part of an interim program assessment that was published by the NIDDK in April, 2003 http://www.nidk.nih.gov/federal/planning/type_1_specialfund/. This revised survey will contribute to a statutorily mandated report, due to Congress on January 1, 2007, evaluating the process and efforts under this program and assessing research initiatives funded by these Acts of Congress.

Frequency of Response: The initial survey will require a one time response; though, respondents may be contacted again in the event of future congressionally mandated reports on the

use of the special type 1 diabetes research funds.

Affected Public: Research scientists who received the special funds about which Congress has mandated in law the requirements for an evaluation report. **Type of Respondents:** Laboratory and clinical investigators who have received support from the special type 1 diabetes funds provided under the laws previously cited. The annual reporting burden is as follows: **Estimated Number of Respondents:** 500; **Estimated Number of Responses per Respondent:** 1 (Respondents will be given one questionnaire containing an estimated fifteen questions.); **Average Burden Hours Per Response:** 1; and **Estimated Total Annual Burden Hours Requested:** 500. The annualized total cost to respondents is estimated at: \$25,000. It is expected that the respondents will be contacted via e-mail and that their responses will be collected through an Internet-accessible questionnaire. These measures will reduce the burden on the respondents and the overall costs of administering the study. Because different types of awards have been made with the special type 1 diabetes funds, the questionnaire may be tailored such that respondents will only be asked to answer a subset of questions that pertain to their particular type of award(s). No respondent will be asked to answer more than a total of fifteen questions, at least one-third of which will be answered with a "yes" or "no" or a one-word response. There are no Capital Costs, Operating or Maintenance Costs to report.

Request For Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and

instruments, contact Dr. Shefa Gordon, Office of Scientific Program and Policy Analysis, NIDDK, NIH, Building 31, Room 9A31, 9000 Rockville Pike, Bethesda, MD 20892, or call non-toll-free number 301-496-6623 or e-mail your request, including your address to: gordonshefa@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: March 2, 2005.

Lynell Nelson,

Project Clearance Liaison, NIDDK, National Institutes of Health.

[FR Doc. 05-4674 Filed 3-9-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Dimer Inhibitory Peptides of CXCR4 as a Possible Novel Therapy for Cancer

Jinhai Wang and Michael Norcross (FDA),

DHHS Reference No. E-037-2005/0—
Research Tool,

Licensing Contact: John Stansberry;
(301) 435-5236;
stansbej@mail.nih.gov.

This invention may control or inhibit cancer metastases by targeting